The Central Drugs Standard Control Organisation (CDSCO) has recently flagged over 50 drugs as “not of standard quality” (NSQ). This alarming revelation has significant implications for public health and safety. Here are the key points you need to know:
- Scope of the Issue: The CDSCO identified over 50 drugs, including widely used medications like Paracetamol and Pantoprazole, as sub-standard.
- Types of Medications Affected: The list includes a variety of drugs such as calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines.
- Specific Drugs Highlighted: Notable mentions include Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd, and calcium and vitamin D3 tablets from Pure & Cure Healthcare Pvt. Ltd.
- Geographical Spread: The sub-standard drugs were produced in various regions, including Himachal Pradesh, Hyderabad, Waghodia, Vadodara, Andhra Pradesh, and Indore.
- Pharmaceutical Companies Involved: Companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), and Meg Lifesciences were among those flagged.
- Industry Response: Some pharmaceutical companies have denied responsibility, claiming that the flagged drugs are spurious and not manufactured by them.
- Regulatory Actions: The CDSCO conducts monthly random sampling to ensure drug quality, and this report is part of their ongoing efforts to maintain high standards.
- Public Health Concerns: The failure of commonly used drugs like Paracetamol to meet quality standards raises significant public health concerns, especially for medications used for pain and fever relief.
- Historical Context: This is not the first time the CDSCO has flagged sub-standard drugs. Previous reports have also highlighted similar issues, indicating a persistent problem in the pharmaceutical industry.
- Consumer Awareness: It is crucial for consumers to stay informed about the quality of medications they use and to report any adverse effects to healthcare providers immediately.
-
Top 10 Mid Cap Mutual Funds With the Best 1-Year Returns in 2026—Which Fund Is Leading the Race?
Top 10 Mid Cap Mutual Funds With the Best 1-Year Returns in 2026—Which Fund Is Leading the Race? Mutual Funds — India 2026 Top 10 Mid Cap Mutual Funds With the Best 1-Year Returns in 2026—Which Fund Is Leading the Race? Updated July 2026 · 13 min read · Compiled from AMFI-disclosed NAV data, fund-house…
-
Key Economic Drivers: How GDP Growth and CPI Inflation Impact Your Portfolio
The Indian stock market on July 23, 2026, presents a dynamic landscape where the Nifty 50 is navigating resistance near the 23,996 level and the BSE Sensex is balancing robust domestic growth against global headwinds. Driven by strong Q4 FY26 GDP growth of 7.8% and mixed corporate earnings, the current market offers targeted opportunities for…
-
Indian Stock Market Trends: The Complete July 22, 2026 Briefing on Sensex, Nifty, Banks, Sectors and Stock Ideas
Indian stock market trends on Wednesday, July 22, 2026, are being shaped by a delicate balance: resilient domestic growth and easier interest rates on one side, versus earnings scrutiny, global risk appetite, currency pressures and valuation discipline on the other. India’s FY26 real GDP growth is officially estimated at 7.6%, while the RBI’s policy repo rate…
-
Indian Stock Market Trends: Will July 2026’s Volatility Create the Next Big Buying Opportunity?
Indian stock market trends in July 2026 point to a market caught between resilient domestic fundamentals and a more difficult global backdrop. The BSE Sensex closed near 77,709 on 20 July, down 0.57% for the session, while the recent trading narrative has featured pressure on banking shares, selective strength in defensives, and heightened sensitivity to…
-
HDFC Bank Stock Plunges Over 5% Despite ₹19,060 Crore Profit: What Investors Are Really Worried About
HDFC Bank just posted a record ₹19,060 crore profit, yet investors dumped the stock within hours, wiping out over 5% in a single session. What hidden number inside the earnings report triggered this panic despite the record-breaking headline? The real story isn’t the profit. It’s what’s quietly shrinking beneath it. HDFC Bank, India’s largest private…
-
Government Says No Proposal to Offer Long-Term Tax Relief for Domestic Equity Investors: What It Means for Your Portfolio
Millions of Indian investors have been waiting for one thing: relief from equity taxes. Parliament just delivered its answer, and it’s not what anyone hoped. Behind the “no proposal” statement lies a startling revenue number, a quiet foreign investor exemption, and a tax rule quietly reshaping how India invests. Here’s what actually changed. If you…





